NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 87 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $672,000 | – | 250,000 | – | 0.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AH Equity Partners Bio II, L.L.C. | 16,298,006 | $34,552,000 | 24.08% |
| Madrona Venture Group, LLC | 6,020,770 | $12,764,000 | 5.87% |
| AH Equity Partners LSV II, L.L.C. | 1,355,911 | $2,875,000 | 2.57% |
| Tikvah Management LLC | 1,488,895 | $3,156,000 | 1.46% |
| ArchPoint Investors | 1,449,551 | $3,073,000 | 1.26% |
| Ally Bridge Group (NY) LLC | 823,974 | $1,747,000 | 1.15% |
| Perceptive Advisors | 9,111,151 | $19,315,000 | 0.56% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $4,240,000 | 0.51% |
| BRIDGER MANAGEMENT, LLC | 413,700 | $877,000 | 0.27% |
| Decheng Capital Management III (Cayman), LLC | 300,000 | $636,000 | 0.23% |